Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CryptiVax-1001
- Development stage
- Phase 1
- Lead developer
- Epitopea
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Parenteral
01
Overview
CryptiVax-1001 is an off-the-shelf, multivalent mRNA-based therapeutic cancer vaccine developed by Epitopea. It utilizes the company's proprietary CryptoMap platform to identify and target 'Cryptigens'—a novel class of shared, aberrantly expressed tumor-specific antigens (aeTSAs) derived from previously overlooked non-coding regions of the 'dark genome.' By delivering mRNA encoding multiple Cryptigens, the therapy is designed to activate a robust and durable T-cell mediated immune response against cancer cells. Its primary indication is high-grade serous ovarian cancer (HGSOC), specifically as a frontline maintenance therapy for patients with HRP+/BRCA-wild-type tumors who have limited treatment options following standard chemotherapy.
- Brand names
- CryptiVax-1001CryptiVax1001CryptiVax 1001
- Other names
- CryptiVax
02
Targets
pMHC (Peptide-MHC complex family)
Beyond the preview
Go deeper on CryptiVax-1001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CryptiVax-1001.